Home › Funds › ORBIMED ADVISORS LLC › SNDX
ORBIMED ADVISORS LLC position in SNDX
SYNDAX PHARMACEUTICALS INC · Health Care
ORBIMED ADVISORS LLC reported holding 1,542,000 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$33.7M, representing 0.68% of its reported portfolio and ranking #39 among its reported holdings. ORBIMED ADVISORS LLC has disclosed SNDX holdings in 7 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's SNDX position evolved
ORBIMED ADVISORS LLC first disclosed a stake in SNDX in Q3 2023 at 1,284,000 shares (US$18.6M). The position peaked in Q1 2024 at 1,749,000 shares, worth US$41.6M. Across 7 filings, ORBIMED ADVISORS LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,542,000 shares valued at US$33.7M — an increase of 579,700 shares quarter over quarter.. Notable position changes include a 36% increase in Q4 2023 (shares rose 10% over the following quarter), a 60% increase in Q2 2026 (shares fell 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.28M | $18.64M | New |
| Q4 2023 | 1.75M | $37.80M | Add |
| Q1 2024 | 1.75M | $41.63M | Hold |
| Q2 2024 | 1.93M | $39.53M | Add |
| Q3 2024 | 1.93M | $37.06M | Hold |
| Q1 2026 | 962.30K | $22.48M | New |
| Q2 2026 | 1.54M | $33.71M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SNDX and 13F data
SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SNDX
- Kynam Capital Management, LP 8.05M sh · $175.99M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M sh · $82.63M · Q2 2026
- Eversept Partners, LP 2.80M sh · $61.17M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $54.65M · Q2 2026
- Elmind Capital, LP 1.85M sh · $40.55M · Q2 2026
- Soleus Capital Management, L.P. 1.63M sh · $35.59M · Q2 2026
- MPM BioImpact LLC 1.33M sh · $29.15M · Q2 2026
- Aisling Capital Management LP 1.32M sh · $28.79M · Q2 2026
- Catalio Capital Management, LP 1.22M sh · $26.58M · Q2 2026
- Prosight Management, LP 1.20M sh · $26.23M · Q2 2026
- Trails Edge Capital Partners, LP 1.11M sh · $24.26M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.01M sh · $22.18M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held SNDX?
ORBIMED ADVISORS LLC has disclosed SNDX holdings in 7 of the last 12 reported quarters, going back to Q3 2023.
What is ORBIMED ADVISORS LLC's current position in SNDX?
As of Q2 2026, ORBIMED ADVISORS LLC holds 1.54M shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $33.71M, representing 0.68% of its reported portfolio and ranking #39.
Has ORBIMED ADVISORS LLC been buying or selling SNDX?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in SNDX. The position peaked in Q1 2024 at 1.75M shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.